STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment install, maintain, upgrade, repair, and troubleshoot services. This segment provides its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, including instrument and endoscope repair and maintenance solutions; and custom process improvement consulting and outsourced sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services using gamma, electron beam, and X-ray technologies, as well as ethylene oxide and hydrogen peroxide; and laboratory testing services. It operates a network of approximately 50 facilities. The company was founded in 1985 and is based in Derby, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:STE
Previous Symbol
CUSIP85915210
Phone44-13-3238-7100
Debt
Debt-to-Equity Ratio0.43
Current Ratio2.65
Quick Ratio2.02
Price-To-Earnings
Trailing P/E Ratio25.19
Forward P/E Ratio22.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.62 billion
Price / Sales3.42
Cash Flow$6.2549 per share
Price / Cash16.95
Book Value$37.92 per share
Price / Book2.80
Profitability
EPS (Most Recent Fiscal Year)$4.15
Net Income$290.91 million
Net Margins11.42%
Return on Equity11.80%
Return on Assets7.17%
Miscellaneous
Employees12,000
Outstanding Shares84,550,000
Market Cap$9.02 billion
OptionableN/A
Steris (NYSE:STE) Frequently Asked Questions
What is Steris' stock symbol?
Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
How often does Steris pay dividends? What is the dividend yield for Steris?
Steris declared a quarterly dividend on Wednesday, August 8th. Investors of record on Wednesday, August 29th will be given a dividend of $0.34 per share on Thursday, September 27th. This represents a $1.36 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend is Tuesday, August 28th. This is a positive change from Steris's previous quarterly dividend of $0.31. View Steris' Dividend History.
How were Steris' earnings last quarter?
Steris PLC (NYSE:STE) issued its quarterly earnings results on Wednesday, August, 8th. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.01. The medical equipment provider earned $638.76 million during the quarter, compared to analysts' expectations of $638.63 million. Steris had a return on equity of 11.80% and a net margin of 11.42%. The business's revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.85 EPS. View Steris' Earnings History.
When is Steris' next earnings date?
What guidance has Steris issued on next quarter's earnings?
Steris updated its FY19 earnings guidance on Wednesday, August, 8th. The company provided earnings per share guidance of $4.63-4.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.70.
What price target have analysts set for STE?
6 analysts have issued 1 year price targets for Steris' shares. Their forecasts range from $16.00 to $125.00. On average, they anticipate Steris' stock price to reach $98.00 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Steris.
What is the consensus analysts' recommendation for Steris?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Steris.
What are Wall Street analysts saying about Steris stock?
Here are some recent quotes from research analysts about Steris stock:
- 1. According to Zacks Investment Research, "Over the past six months, STERIS has been outperforming its industry. However, a tough competitive landscape and currency headwinds continue to pose threats to STERIS. Moreover, customer consolidation is a concern for the company. On a brighter note, we are encouraged by the favorable underlying market trends along with STERIS' new product and service offerings. The company's strong organic growth across Healthcare Products, Healthcare Specialty Services, Applied Sterilization Technologies and Life Sciences segments also buoys optimism. Further, growth in free cash flow reserve is indicative of the company’s cash balance strength. The company has also made certain divestments and organizational changes, which are expected to better suit its operations." (10/9/2018)
- 2. KeyCorp analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $21.3/share, as a 25x multiple of taxed and diluted $11.7 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.3/ share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/9/2018)
Who are some of Steris' key competitors?
Some companies that are related to Steris include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), Align Technology (ALGN), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Halyard Health (HYH), Sientra (SIEN), Establishment Labs (ESTA), Invacare (IVC) and RTI Surgical (RTIX).
Who are Steris' key executives?
Steris' management team includes the folowing people:
- Mr. Walter M. Rosebrough Jr., CEO, Pres & Director (Age 64)
- Mr. Michael J. Tokich, Sr. VP & CFO (Age 49)
- Mr. Daniel A. Carestio, Chief Operating Officer (Age 45)
- Mr. John Adam Zangerle, VP, Gen. Counsel & Sec. (Age 51)
- Dr. Adrian Vincent Coward, Sr. VP of Healthcare Specialty Services (Age 48)
Who are Steris' major shareholders?
Steris' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.37%), Legato Capital Management LLC (0.14%), BTIM Corp. (0.13%), West Coast Financial LLC (0.10%), Texas Permanent School Fund (0.06%) and Aperio Group LLC (0.03%). Company insiders that own Steris stock include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Institutional Ownership Trends for Steris.
Which institutional investors are selling Steris stock?
STE stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, BTIM Corp., Callahan Advisors LLC, Texas Permanent School Fund and State of Alaska Department of Revenue. Company insiders that have sold Steris company stock in the last year include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Insider Buying and Selling for Steris.
Which institutional investors are buying Steris stock?
STE stock was bought by a variety of institutional investors in the last quarter, including Fruth Investment Management, Legato Capital Management LLC, Biltmore Wealth Management LLC, Oakbrook Investments LLC, First Citizens Bank & Trust Co., Nisa Investment Advisors LLC, We Are One Seven LLC and Private Trust Co. NA. View Insider Buying and Selling for Steris.
How do I buy shares of Steris?
Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steris' stock price today?
One share of STE stock can currently be purchased for approximately $106.02.
How big of a company is Steris?
Steris has a market capitalization of $9.02 billion and generates $2.62 billion in revenue each year. The medical equipment provider earns $290.91 million in net income (profit) each year or $4.15 on an earnings per share basis. Steris employs 12,000 workers across the globe.
What is Steris' official website?
How can I contact Steris?
Steris' mailing address is Rutherford House Stephensons Way Chaddesden, Derby X0, DE21 6LY. The medical equipment provider can be reached via phone at 44-13-3238-7100 or via email at [email protected]
MarketBeat Community Rating for Steris (NYSE STE)
MarketBeat's community ratings are surveys of what our community members think about Steris and other stocks. Vote "Outperform" if you believe STE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STE will underperform the S&P 500 over the long term. You may vote once every thirty days.
